Skip to Content
Merck
All Photos(1)

Documents

305R-1

Sigma-Aldrich

Cytokeratin 5 (EP1601Y) Rabbit Monoclonal Primary Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP1601Y, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (305R-14)
vial of 0.5 mL concentrate (305R-15)
bottle of 1.0 mL predilute (305R-17)
vial of 1.0 mL concentrate (305R-16)
bottle of 7.0 mL predilute (305R-18)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

isotype

IgG

control

mesothelioma, prostate

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... KRT5(3852)

General description

Cytokeratin 5 is an intermediate filament protein of 58 kD molecular weight within the cytokeratin family. It is a type II (basic) cytokeratin. Antibodies to this protein identify basal cells of squamous and glandular epithelia, myoepithelia, and mesothelium. Anti-cytokeratin 5 has been useful in the differential diagnosis of metastatic carcinoma in the pleura versus epithelioid mesothelioma. Epithelioid mesotheliomas are strongly positive in almost all cases, but up to 11% of pulmonary adenocarinomas will show focal immunoreactivity. Almost all squamous cell carcinomas, half of transitional carcinomas, and many undifferentiated large cell carcinomas immunostain with anti-CK 5. Anti-CK 5, along with anti-p63, affords a high sensitivity and specificity for squamous differentiation. Myoepithelial cells of the breast, glandular epithelia, and basal cells of the prostate are labeled with anti-CK 5. This antibody, along with anti-CK 14, has found application in identifying basal-like breast carcinoma, a tumor with poor prognosis. Some carcinomas of ovarian origin may display anti-CK 5 positivity.

Quality


IVD
IVD
IVD
RUO

Linkage

Cytokeratin 5 Positive Control Slides, Product No. 305S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Catherine L Clarke et al.
The Journal of pathology, 204(2), 147-152 (2004-09-18)
In recent studies, Böcker and colleagues described a population of cells in paraffin wax sections of normal human breast that express cytokeratins (CK) 5/6 without expression of CK8/18 or smooth muscle actin (SMA). They proposed that these represent stem cells
A Douglas-Jones et al.
Histopathology, 47(2), 202-208 (2005-07-28)
To investigate agreement on core biopsy diagnosis of papillary breast lesions, which is acknowledged as a difficult area, and to determine the effect of the use of immunohistochemistry (IHC) to assist diagnosis. Haematoxylin and eosin (H&E) sections of 129 core
David J Dabbs et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 19(11), 1506-1511 (2006-08-31)
The basal phenotype of breast carcinoma was demonstrated from a study of gene expression profiles, which demonstrated five carcinoma phenotypes with differing immunohistologic profiles and outcomes. The basal phenotype, so-named because of an immunohistologic profile that is similar to myoepithelial
Chad A Livasy et al.
Human pathology, 38(2), 197-204 (2007-01-20)
Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The
Camilla E Comin et al.
The American journal of surgical pathology, 31(8), 1139-1148 (2007-08-02)
Distinguishing between epithelioid peritoneal mesothelioma and papillary serous carcinomas involving the peritoneum may be very difficult, owing to overlapping morphologic features. Immunohistochemistry may facilitate establishing a correct diagnosis, but, as no single antibody has demonstrated absolute sensitivity and specificity for

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service